Transforming growth factor-beta receptor type 1 (TGFBR1) (TGFBR1)

Transforming growth factor-beta receptor type 1 (TGFBR1), also known as ALK5, is a transmembrane serine/threonine kinase that serves as a critical transducer of TGF-beta superfamily signals [UniProt: P36897]. Upon ligand binding to the type 2 receptor, TGFBR1 is recruited, phosphorylated, and activated, subsequently phosphorylating downstream Smad2 and Smad3 proteins to regulate gene transcription [PubMed: 24631444]. This pathway governs essential cellular processes, including proliferation, differentiation, and the production of extracellular matrix components. In the context of disease, TGFBR1 is a major driver of tissue fibrosis and plays a complex role in oncology, where it can act as a tumor suppressor in early stages but promotes metastasis and immune suppression in advanced cancers [PubMed: 30635931]. Therapeutic targeting of TGFBR1 primarily involves small molecule kinase inhibitors designed to block the Smad signaling cascade. Clinical development of these inhibitors has focused on oncology and fibrotic disorders, though concerns regarding cardiovascular and skin toxicity remain significant hurdles for long-term administration [PubMed: 26045011].

Other names

ALK5ALK-5SKR3ACVRLK4TGF-beta receptor type IActivin receptor-like kinase 5TGF-beta receptor type 1

Small molecule inhibitors act as ATP-competitive antagonists of the TGFBR1 serine/threonine kinase domain, preventing the phosphorylation of R-Smads (Smad2 and Smad3) and thereby blocking the canonical TGF-beta signaling pathway [PubMed: 24631444].